You do not have permission to view this document: [5934647]!
Study Start Date: 01/01/2010
Study End Date: 07/01/2011
MHC haplotyping in dogs with Acquired Myasthenia Gravis
Published study results can be found here.
Acquired myasthenia gravis (MG) is an immune mediated disease. It is a relatively common disease in dogs, and although many dogs go into spontaneous remission, MG can have a devastating effect if not recognized early and treated appropriately. In people, there is an association between genes (HLA DR3) and myasthenia gravis. If the same is true in dogs, it may allow us to indentify dogs at risk before the development of disease, and it may allow us to develop new treatments.
Study Design:
Prospective case-control study
Sample Size:
na
Inclusion Criteria:
- Confirmation of a diagnosis of acquired MG by demonstration of a positive acetylcholine receptor antibody titer (UCSD).
Exclusion Criteria:
- Negative acetylcholine receptor antibody titer
Study Controls:
Dogs without MG will be used as controls.
Samples:
For this study, we need:
-
two tubes of refrigerated EDTA blood
-
a copy of the dog's pedigree (if available)
-
a signed consent form
to be submitted to the UC Davis Neurology/Neurosurgery Service. Dogs may be brought to UC Davis to have blood samples collected or the blood can be shipped by overnight courier. While there is no charge for the DNA testing, there is no financial compensation for owners participating in this study.
Files for Download:
Client Consent form.
Study Website
Costs/Reimbursements
Investigators will cover sample submission costs. Contact Dr. Vernau for details.
You do not have permission to view this document: [5934681]!
Full Disclosure Information:
- The study is funded by an institutional (intramural) grant.
- The investigator does not have a conflict of interest.
- The study will be published if results are negative.
- The study will be reported on VIN.
- The authors will acknowledge VIN if the study is published and VIN contributed to substantial case recruitment.